Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
20,758.00 | 22,051.00 | 20,102.00 | 18,562.00 |
+8 more quarters Free account |
Receivables |
19,046.00 | 17,721.00 | 17,178.00 | 17,611.00 | |
Inventory |
15,144.00 | 14,583.00 | 14,191.00 | 14,146.00 | |
Total current assets |
59,774.00 | 59,173.00 | 55,624.00 | 54,611.00 | |
Property, Plant, Equpment (Net) |
23,582.00 | 23,270.00 | 23,169.00 | 22,338.00 | |
Goodwill and Intangible Assets (Total) |
96,708.00 | 97,619.00 | 99,175.00 | 96,785.00 | |
Long Term Assets (Tax, Deferred) |
6,728.00 | 6,727.00 | 6,874.00 | 6,666.00 | |
Long-term assets (Other) |
14,269.00 | 14,105.00 | 14,368.00 | 12,416.00 | |
Total non-current assets |
141,287.00 | 141,721.00 | 143,586.00 | 138,205.00 | |
Total Assets |
201,061.00 | 200,894.00 | 199,210.00 | 192,816.00 | |
Notes Payable |
11,692.00 | 17,460.00 | 8,495.00 | 6,387.00 | |
Accounts Payable |
9,223.00 | 10,460.00 | 11,991.00 | 9,625.00 | |
Accrued Expenses |
32,929.00 | 28,709.00 | 32,252.00 | 32,929.00 | |
Current Part of Taxes to Pay |
1,051.00 | 1,087.00 | 1,388.00 | 1,928.00 | |
Total current liabilities |
54,895.00 | 57,716.00 | 54,126.00 | 50,869.00 | |
Long Term Debt (Total) |
37,344.00 | 37,527.00 | 39,438.00 | 39,408.00 | |
Pension and Post-Retirement Liabilities |
6,657.00 | 6,760.00 | 6,957.00 | 6,930.00 | |
Long Term Tax Liability (Deferred) |
6,608.00 | 7,011.00 | 6,791.00 | 5,988.00 | |
Non-current Liabilities (Other) |
10,586.00 | 10,694.00 | 10,354.00 | 10,344.00 | |
Total non-current liabilities |
61,195.00 | 61,992.00 | 63,540.00 | 62,670.00 | |
Total liabilities |
116,090.00 | 119,708.00 | 117,666.00 | 113,539.00 | |
Common Stock (Net) |
3,120.00 | 3,120.00 | 3,120.00 | 3,120.00 | |
Retained Earnings |
171,665.00 | 169,161.00 | 168,978.00 | 167,281.00 | |
Treasury Stock |
75,863.00 | 76,264.00 | 75,624.00 | 75,887.00 | |
Common Equity (Total) |
84,971.00 | 81,186.00 | 81,544.00 | 79,277.00 | |
Shareholders Equity (Total) |
84,971.00 | 81,186.00 | 81,544.00 | 79,277.00 | |
Shareholders Equity and Liabilities (Total) |
201,061.00 | 200,894.00 | 199,210.00 | 192,816.00 | |
Shares (Common) |
2,408.23 | 2,406.59 | 2,407.94 | 2,406.20 | |
Shareholders Equity (Tangible) |
(11,737.00) | (16,433.00) | (17,631.00) | (17,508.00) | |
Net Debt |
16,586.00 | 15,476.00 | 19,336.00 | 20,846.00 | |
Total Debt |
37,344.00 | 37,527.00 | 39,438.00 | 39,408.00 |